The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3.
Sridhar VS, Heerspink HJL, Davies MJ, Banks P, Girard M, Garg SK, Cherney DZI. The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3. Diabetes Care. 2023 07 01; 46(7):e133-e135.